Ladder Bio is a therapeutics company that develops synthetic, ladder-shaped compounds engineered for high specificity and stability.
Ladder Bio (formerly ThirdLaw Molecular) has raised $5.5M in total funding. The most recent round was Seed. The last funding was announced in October 2025.
Ladder Bio (formerly ThirdLaw Molecular)'s investors include SmartGateVC, Medical Excellence Capital, Defense Threat Reduction Agency (DTRA), Hatch Biofund Management, Bowman’s Tower Venture Partners.
Ladder Bio (formerly ThirdLaw Molecular) is headquartered in Blue Bell, United States.
Ladder Bio is a therapeutics company that develops synthetic, ladder-shaped compounds engineered for high specificity and stability.
Ladder Bio (formerly ThirdLaw Molecular) is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ladder Bio (formerly ThirdLaw Molecular) — Funding & Investors." VCBacked, October 8, 2025, https://www.vcbacked.co/company/ladder-bio-formerly-thirdlaw-molecular. Accessed August 1, 2026.
VCBacked. (2025). Ladder Bio (formerly ThirdLaw Molecular) — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/ladder-bio-formerly-thirdlaw-molecular
{{cite web |title=Ladder Bio (formerly ThirdLaw Molecular) — Funding & Investors |url=https://www.vcbacked.co/company/ladder-bio-formerly-thirdlaw-molecular |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated